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ABSTRACT 
 
BACKGROUND 
Robotic assisted radical cystectomy with intracorporeal urinary diversion (iRARC) is 
an attractive option to open cystectomy but the benefit in terms of improved 
outcomes are not established. 
 
OBJECTIVES 
To evaluate early postoperative morbidity and mortality of patients undergoing 
iRARC and conduct a critical analysis of complications using a standardise reporting 
criteria as stratified according to urinary diversion.  
 
DESIGN, SETTING AND PARTICIPANTS 
134 patients underwent iRARC for bladder cancer at a single centre between June 
2011 and July 2015.  
 
INTERVENTION 
Radical cystectomy with intracorporeal urinary diversion. 
 
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS  
Patient demographics, pathological data and 90-day perioperative mortality and 
complications were recorded. Complications were reported according to the Clavien-
Dindo (CD) classification and stratified according to urinary diversion type and either 
surgical or medical complications. Chi square test and t-test were used for 
categorical and continuous variables respectively. Multivariable logistic regression 
was performed on variables with significance in univariate analysis. 
 
RESULTS AND LIMITATIONS 
The 90-day all complication rate following ileal conduit and continent diversion was 
68% and 82.4% while major complications were 21.0% and 20.6% respectively. 90-
day mortality was 3% and 2.9% for ileal conduit and continent diversion patients 
respectively. On multivariate analysis, blood transfusion requirement was 
independently associated with major (p=0.002) and all 30-day (p=0.002) and 90-day 
major complications (p=0.012) while male patients were associated with 90-day 
major complications (p=0.015). Critical analysis identified surgical complications was 
responsible for 39.4% of all 90-day major complications. The incidence of surgical 
complications did not decline with increasing number for iRARC cases performed 
(p=0.742, r=0.31). Limitations of this study include its retrospective nature, limited 
sample size and limited multivariate analysis due to low number of events.  
 
CONCLUSION 
Although complications following iRARC are common, most are low grade. A critical 
analysis identified surgical complications as a cause of major complications and 
addressing this issue could have a significant impact in lowering morbidity 
associated with iRARC.   
 
PATIENT SUMMARY 
In this report, we looked at the surgical outcomes in bladder cancer patients treated 
with minimal invasive robotic surgery. We found that surgical complications account 
for most major complications and previous surgical experience may be a 
confounding factor when interpreting results from different center even in a 
randomised trial setting.  
 
 
 
 
 
 
1. INTRODUCTION 
 
Radical cystectomy with lymphadenectomy is the standard of care for patients with 
muscle invasive bladder cancer (MIBC) and selected high risk non-muscle invasive 
bladder cancer (NMIBC). Risk factors for bladder cancer include advancing age, 
tobacco smoking and exposure to industrial carcinogens, resulting in a patient cohort 
with a high incidence of concurrent cardiovascular and pulmonary disease. In 
addition to pre-existing co-morbidity, the extent of surgery including urinary diversion 
places patients undergoing radical cystectomy at significant risk of postoperative 
complications [1].    
 
Early oncological outcomes have suggested no significant difference between 
robotic assisted radical cystectomy with intracorporeal urinary diversion (iRARC) and 
open radical cystectomy (ORC) [2]. An aim of minimal invasive surgery (MIS) is to 
replicate principles of open surgery with the added advantage of reducing the risk of 
postoperative complications and allow an early return to normal activity [3]. In the 
context of radical cystectomy, the MIS has particular relevance as the complication 
rate for ORC is over 60%, with a significant 90-day mortality rate of 5.1%, having 
fallen from as high as 10.3% [4-6]. Despite evidence that minimal invasive surgery 
has benefits over open surgery [7] comparison between the outcomes of open and 
robotic assisted radical cystectomy (RARC) has not demonstrated major differences. 
Results from a randomised controlled trial by Bochner et al. which compared ORC 
with RARC, showed a significantly lower blood loss and longer operating time in the 
RARC arm, but no difference in Clavien-Dindo (CD) II-IV complications and length of 
stay (LOS) [8]. The requirement to convert to open extracorporeal urinary diversion 
may mask potential benefits of the minimal access approach.   
 
In this paper, we evaluate 90-day perioperative morbidity and mortality in 134 iRARC 
cases stratified according to type of urinary diversion, CD classification, with 
complications attributed to surgical or medical aetiology.  
 
2. PATIENTS AND METHODS 
2.1 Patient population 
Data on cases undergoing iRARC are prospectively recorded and maintained using 
an institutional approved database. iRARC was commenced in June 2011 and 
between June 2011 and July 2015, 163 radical cystectomies were performed. 134 
patients underwent iRARC while 29 patients who underwent planned open radical 
cystectomy due to previous abdominal surgery or patient / surgeon preference were 
excluded from analysis. All cases were performed by two surgeons. Since January 
2013, 93.4% (113/121) of cystectomy procedures performed have been iRARC 
which is now the default procedure at our institution with 63 radical cystectomy cases 
performed in 2015. All patients undergoing iRARC had MIBC or high risk NMIBC. 
Intracorporeal urinary diversion was either ileal conduit or continent diversion 
(neobladder or Mitrofanoff). This study was part of a quality assurance programme 
and registered with our institutional department (Urology2015.2). 
 
2.2 Surgical technique 
The technique for iRARC has previously been previously described [9]. Briefly, a 
standard 6 port transperitoneal approach with the patient in 27°Trendelenburg was 
used. Pelvic lymph node dissection included external, internal, common iliac and 
obturator fossa lymph nodes. Specimens were retrieved using an Endocatch bag 
(Covidien, Dublin, Ireland) which was removed via the vagina if possible in female 
patients or otherwise via an iliac fossa incision in all others. The left ureter was 
passed posteriorly to the sigmoid mesocolon. Ileal conduit was constructed by 
mobilising a 15 cm segment of terminal ilium 15 cm from the ileo-caecal valve using 
a laparoscopic 60 mm intestinal stapler (Endo-GIA; Covidien Corp., Dublin, Ireland). 
Continent diversion was constructed using a 50 cm segment of ileum. Uretero-ileal 
anastomosis for the ileal conduit and continent diversion was performed using either 
a Bricker or Wallace anastomoses depending on surgeon preference. 6F infant 
feeding tubes/ Bander stents were used as ureteric stents and externalised.  
 
2.3 Data collected 
Patient demographics, clinical and pathological characteristics, perioperative 
variables, transfusion requirements, hospital length of stay (LOS) and standardised 
complication data were prospectively recorded. Preoperative cardiopulmonary 
exercise testing (CPET) variables such as anaerobic threshold (AT), peak oxygen 
consumption (Peak VO2) and minute ventilation-carbon dioxide production (VE/ 
VCO2) were also recorded. All patients were followed up for a minimum of 90 days 
post-surgery.  
 2.4 Study outcomes measured 
Thirty and 90-day complications were classified according to the modified Memorial 
Sloan-Kettering Cancer Center (MSKCC) CD system [4]. Minor and major 
complications were defined as CD I-II and CD III-IV respectively. Complications were 
divided to: surgical complications which were defined as urinary leak, anastomotic 
stricture, significant bleeding, or herniation and wound dehiscence; and medical 
complications were defined as organ dysfunction, sepsis or bowel related not arising 
from a surgical cause. Ileus was defined as persistent post-operative vomiting 
requiring a nasogastric tube insertion or inability to tolerate enteral intake for ≥48 
hours. 
 
2.5 Statistical methods  
Descriptive statistics used to report continuous data which included mean, median, 
interquartile range (IQR), standard deviation and confidence interval (95% CI). Chi 
square test and t-test were used for categorical and continuous variables 
respectively. Pearson’s correlation coefficient was used to determine correlation. 
Multivariable logistic regression were performed on variables with significance in 
univariate analysis. Statistical significance was set at p value <0.05. Statistical 
analysis was performed using SPSS v22 (IBM, New York, USA).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
3. RESULTS 
Patient demographic data for 100 ileal conduit cases and 34 continent diversion 
cases are detailed in Table 1. There were significantly more patients with ASA score 
of ≤2 (p≤0.001) in the continent diversion group compared to the ileal conduit group. 
Consistent with this was a reduced physical fitness in patients undergoing ileal 
conduit reflected by a CPET variables (all p<0.05) compared to patients undergoing 
continent diversion. Five ileal conduit patients required open conversion: two patents 
had extensive locally advanced stage T4 disease, two had significant intraperitoneal 
adhesions, one of which was converted following identified bowel injury and one 
case was a salvage procedure.  
 
Histopathological outcomes are listed on Table 1. Ileal conduit cases were of more 
advanced histopathological stage (≥pT3) compared to continent diversion (26.0% vs 
11.7%, p=0.038). Positive nodal disease was five times more common in the ileal 
conduit group compared to continent diversion (20.0% vs 4.8%; p=0.016).   
 
The overall 30-day complication rate was 52.0% and 61.8% for ileal conduit and 
continent diversion patients respectively (p=0.323), while the 30-day major 
complication rate was 16.0% and 14.7% (p=0.858) (Table 2). The 90-day all 
complication rate was 68.0% and 82.4% for ileal conduit and continent diversion 
patients (p=0.109) respectively with a major complication rate of 21.0% and 20.6% 
(p=0.959). Overall post-operative ileus developed in 23.1% (n=31). Patients who 
developed ileus were significantly more likely to develop a 30-day (35.5% vs 9.7%, 
p=0.001) and 90-day (38.7% vs 15.5%, 0.005) major complication. There was no 
significant difference in 30-day and 90-day major complications or ileus between ileal 
conduit and continent diversion cases.  
 
The overall transfusion rate for iRARC was 21.6%, with no significant difference 
between ileal conduit or continent diversion cases. After excluding 5 patients who 
had an open conversion, ileal conduit and continent diversion transfusion rates were 
20.0% and 14.7% respectively. There was no difference between estimated blood 
loss between ileal conduit and continent diversion groups (p=0.967) (Table 2). 
Overall 90-day mortality was 3.1% (n=4). Three patients (2.2%) in the ileal conduit 
group died within 90 days including two from cardiac events one patient who died 
from carcinomatosis due to T4N0 transitional cell carcinoma with perineural and 
lymphovascular invasion but negative surgical margins. The single continent 
diversion death (0.75%) was due to disseminated intravascular coagulation (DIC) 
following post-operative haemorrhage at day 7 post-surgery. 
 
A critical analysis was conducted for all major complications. Collectively, urinary 
leak, uretero-ileal stricture, wound dehiscence/ abscess, adhesions, incisional hernia 
and significant bleeding which are complications with a clear surgical etiology 
represented 39.4% (13/33) of 90-day major complications. This is followed by non-
wound infection and stent/ drain migration which represents 30.3% (10/33) and 
18.1% (6/33) of 90-day major complications respectively. We did not observe an 
inverse correlation between the number of surgical complications and number of 
iRARC cases performed (p=0.742, r=0.31). Medical complications account for 45.5% 
of 90-day major complications which are mainly attributed to infective causes despite 
the use of prophylactic antibiotics. Medical complications may be harder to minimise 
as patient specific factors are responsible. Table 3 describes 90-day major 
complications according to CD classification while Table 4 describes complications 
according to type of urinary diversion and stratified according to organ system. 
 
Univariate and multivariable analysis of 30-day complications and 90 day 
complications are shown in Table 5 and 6 respectively. Requirement for blood 
transfusion was independently associated with 30-day major complications and 90-
day major complications while male patients were associated with 90-day major 
complications. CPET were associated with either all or major complications.  
 
4. DISCUSSION 
This study reports a comprehensive account of post-operative adverse events 
following iRARC and includes a critical analysis of complications providing insight 
into the evolving technique of iRARC. The 30-day complication rate of 52.0% 
(CD≥III: 16%) and 61.8% (CD≥III: 11.8%) and 90-day complication rate of 68% 
(CD≥III: 21%) and 82.4% (CD≥III: 20.6%) for ileal conduit and continent diversion 
respectively is consistent with that described by the Pasadena Consensus [10-18]. In 
their cumulative analysis, the Pasadena Consensus reported a 30-day complication 
rate of 42%-86% for intracorporeal ileal conduit and 43%-62% for intracorporeal 
continent diversion while the 90-day complication rate for intracorporeal ileal conduit 
was 30%-77% and the data for complications of 90-day continent diversion was not 
reported [19]. The 90-day mortality rate of 3% in the present series is comparable, 
and within 0-8% summarised by Novara and colleagues [19].  
 
The decision about type of urinary diversion is often complex and requires careful 
preoperative assessment, counselling and oncological and patient considerations 
should be taken into account. In this series, patients with continent diversion were on 
average younger, more likely to be ASA ≤ II and with a higher physiological reserve 
according to CPET than those with ileal conduit. Nonetheless, there was no 
difference between 30-day and 90-day complications between ileal conduit and 
continent diversion. 
 
In the current series, patients who developed ileus were significantly more likely to 
develop 30-day (p=0.001) and 90-day (p=0.005) major complications. This indicates 
that the development of ileus may be an early predictor for the development of 
significant postoperative complications as reported by Chang et al. [20]. Compared 
to other series, we report a higher rate of ileus [18, 21] [22]. The development of 
ileus is multifactorial. In the UK, following a Medicines and Healthcare Products 
Regulatory Agency (MHRA) statement restricting the use of non-steroidal anti-
inflammatory drugs in cases with cardiovascular  risk factors, opiate-based analgesia 
is favoured and may be a contributing factor to the development of ileus [23]. In 
addition, the administration of alvimopan, a peripherally acting μ-opioid antagonist, 
has been shown to significantly reduce the risk of ileus but is not licensed for use in 
this setting in the UK [24].  
 
A critical analysis of individual complications has highlighted that a significant 
proportion of morbidity related to iRARC is surgical related. 39.4% of all 90-day 
major complications have a clear surgical aetiology. We believe these results 
highlight that efforts to improve cystectomy outcomes focusing on minimising 
surgical complications may reduce the major complication rates associated with 
iRARC.  
 
 Adopting new technology has an inevitable learning curve and surgical 
complications would decline with increase surgical experience. Although, a 
randomised controlled trial to determine the benefit for iRARC compared to ORC will 
be important, this study highlights that surgeon experience and the learning curve 
associated with iRARC could introduce a profound bias impacting the result. The 
incidence of surgical complications did not decline with increasing number for iRARC 
cases performed (p=0.742, r=0.31). The requirement for a minimum prior surgical 
caseload should be defined before selecting surgeons and centres contributing to 
such trials. The Pasadena Consensus has expressed an opinion that only surgeons 
who have performed >100 RARC cases are considered very experienced [25]. 
Neither the consensus statement nor our own data has defined the learning curve for 
iRARC. For robotic prostatectomy, the learning curve has been defined following 
analysis of large numbers of surgical cases and complications reduce significantly 
after 150 cases [26] while sexual function and urinary incontinence outcomes 
continue to improve and plateau after 600 procedures [27]. It is plausible that 
surgical competency relating to iRARC will be greater than 100 cases and may be 
similar to robotic prostatectomy. 
 
Similar to other studies, the majority of urinary leaks were managed conservatively 
with only 25% (2/8) requiring temporary diversion via nephrostomy insertion [21]. 
While the continent diversion leak rate is lower than that described for extracorporeal 
urinary diversion [21], the very low rates described by Desai and colleagues [22] 
indicate that such surgical complications can be further reduced. The uretero-ileal 
stricture rate of 3.0%, is lower than a recently reported extracorporeal urinary 
diversion series of 6.2% [21] and comparable to other iRARC series [18, 22]. A lower 
incidence of uretero-ileal stricture is consistent with the postulate that extracorporeal 
diversion requires a longer ureteric length, which may promote distal ureteric 
ischemia resulting in ureteric stricture [28].  
 
Gastrointestinal and infection complications represent 61.2% and 41.0% of all 90-
day complications respectively account for most of medical complications. In this 
series, transfusion requirement was independently associated with 30-day and 90-
day major complications. This is consistent with data from 10,100 patients 
undergoing non-cardiac surgery [29]. A recent report also concluded that that 
transfusion requirement is associated with reduced survival in non-anaemic patients 
undergoing radical cystectomy [30]. Requirement for transfusion itself may be a 
surrogate for surgical performance although we did not see a significant association 
between transfusion requirement and surgical complications (surgical complication: 
31.8% vs medical complication: 19.6%, p=0.205). Male patients were independently 
associated with 90-day major complications. This finding may be skewed by the 
three-fold higher number of male patients and that there was a trend towards 
significance between male patients and 90-day major technical complications.  
 
In contrast to a series of extracorporeal RARC, we did not find that the type of 
urinary diversion influenced the development of major complications [21]. Moreover, 
increasing age and poor cardiorespiratory fitness, as indicated by CPET measures 
was not associated with the occurrence of major complications. These findings lend 
support to the idea of reducing surgical complications as a means to improve 
surgical outcomes in patients undergoing iRARC. 
 
We acknowledge there are limitations to this study. Although this study is one of the 
larger iRARC series, our cohort of 134 patients is small compared to ORC series. 
Hence, only a limited multivariate analysis was performed. In addition, results might 
not be generalized to other institutes given that this is a single center study.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. CONCLUSIONS 
Using standardised reporting criteria, complications following iRARC are common, 
although most are low grade. The incidence of surgical complications is possibly 
related to the adoption of a new technology and the report highlights that addressing 
this issue could have a significant impact on morbidity. This study highlights that 
previous surgical experience may be a confounding factor when interpreting results 
from different centers even in a randomized trial setting.  
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Table 1: Patient demographics, preoperative and pathological variables stratified 
according to type of continent diversion. 
 
Variable  Ileal conduit (n=100) Continent diversion 
(n=34) 
P value 
Age, median (IQR) 67.4 (60.4-74.3) 54.5 (48.6-61.6) ≤0.001 
Male  
Female 
75 (75.0) 
25 (25.0) 
28 (82.4) 
6 (17.6) 
0.380 
ASA 
I 
II 
≥III 
 
17 (17.0) 
61 (61.0) 
22 (22.0) 
 
22 (64.7) 
11 (32.4) 
1 (2.9) 
≤0.001 
Preoperative anaemia, men: Hb < 13.0 
g/dL, women: Hb < 12.5 g/dL 
50 (50.0) 7 (20.6) 0.003 
BMI, median (IQR) 27.2 (23.4-31.0) 27.3 (23.0-28.5) 0.893 
LOS, median (IQR) 13.0 (8.7-17.0) 12.0 (9.0-17.0) 0.436 
AT, median (IQR) 10.0 (8.25-11.0) 11.0 (10.0-12.0) ≤0.029 
Peak VO2, median (IQR) 14.0 (12.0-17.8) 18.0 (15.0-21.0) ≤0.001 
VE/ VCO2, median (IQR) 34.0 (31.0-38.7) 30.9 (28.0-34.0) ≤0.001 
NAC  33 (33.0) 13 (38.2) 0.604 
TURBT stage 
pTa 
pT1 
≥pT2 
CIS 
 
4 (4.0) 
23 (23.0) 
69 (69.0) 
4 (4.0) 
 
2 (5.9) 
14 (41.2) 
16 (47.1) 
2 (5.9) 
0.123 
Concurrent CIS 33 (33.0) 13 (38.2) 0.639 
BCG failure 22 (22.0) 9 (26.5) 0.638 
Salvage cystectomy 10 (10.0) 0 (0) 0.054 
Cystectomy stage 
pT0 
cis 
pTa 
pT1 
pT2 
pT3 
pT4 
 
19 (19.0) 
2 (2.0) 
13 (13.0) 
12 (12.0) 
28 (28.0) 
14 (14.0) 
12 (12.0) 
 
14 (41.2) 
3 (8.8) 
5 (14.7) 
3 (8.8) 
5 (14.7) 
1 (2.9) 
3 (8.8) 
0.038 
Soft tissue positive margin 10 (10.0) 0 (0) 0.054 
Number of lymph nodes 13.6±9.0 17.0±8.9 0.066 
Nodal disease 20 (20.0) 1 (4.8) 0.016 
 
Hb: Haemoglobin; ASA: American Society of Anesthesiologist score; BMI: body 
mass index; LOS: length of stay; AT: anaerobic threshold; Peak VO2: maximal 
oxygen consumption; VE/ VCO2: minute ventilation − carbon dioxide production; 
TURBT: transurethral resection of bladder tumour; CIS: carcinoma in situ; BCG: 
Bacillus Calmette–Guérin; NAC: neoadjuvant chemotherapy  
 
Normal reference range for CPET variables: AT ≥ 11ml/kg/min; Peak VO2 ≥ 
15ml/kg/min; VE/ VCO2 ≤ 32 
 Table 2: 30 and 90 day complications stratified according to type of continent 
diversion. 
 
Variable  All patients 
(n=134) 
Ileal conduit 
(n=100) 
Continent 
diversion 
(n=34) 
P 
value 
Length of stay (days), median (IQR) 10.5 (8.0-15.0) 10.0 (8.0-15.5) 11.0 (8.5-14.0) 0.751 
30 day complications (CD grade) 
0 
I 
II 
III 
IV 
V 
 
61 (45.5) 
15 (11.3 )) 
37 (27.6) 
11 (8.2) 
7 (5.2) 
3 (2.2) 
 
48 (48.0) 
9 (9.0) 
27 (27.0) 
8 (8.0) 
6 (6.0) 
2 (2.0) 
 
13 (38.2) 
6 (17.6) 
10 (29.4) 
3 (8.8) 
1 (2.9) 
1 (2.9) 
0.722 
30 day CD ≥III 20 (14.9) 16 (16.0) 4 (11.8) 0.549 
Ileus 31 (23.1) 21 (21.0) 10 (29.4) 0.315 
Urinary leak 8 (6.0) 2 (2.0) 6 (17.6) 0.001 
Estimated blood loss (ml), median (IQR) 300 (225-450) 300 (200- 400) 325 (275-500) 0.967 
Any blood transfusion (≤ 90 days)  29 (21.6) 24 (24.0) 5 (14.7) 0.256 
Blood transfusion (≤ 90 days):   
  Intraoperative 
  Postoperative 
 
15 (11.2) 
19 (14.2) 
 
13 (13.0) 
15 (15.0) 
 
2 (5.9) 
4 (11.8) 
0.633 
Number of units transfused, median 
(IQR) 
1 (1.0-4.0) 2 (1.0-4.0) 2 (1.5-4.0) 0.415 
90 day uretero-ileal stricture 4 (3.0) 3 (3.1) 1 (3.0) 0.993 
90 day complications (CD grade) 
0 
I 
II 
III 
IV 
V 
 
38 (28.3) 
21 (15.7) 
47 (35.1) 
16 (11.9) 
8 (6.0) 
4 (3.0) 
 
32 (32.0) 
18 (18.0) 
29 (29.0) 
11 (11.0) 
7 (7.0) 
3 (3.0) 
 
6 (17.6) 
3 (8.8) 
18 (52.9) 
5 (14.7) 
1 (2.9) 
1 (2.9) 
0.138 
90 day CD ≥III 28 (20.9) 21 (21.0) 7 (20.6) 0.959 
 
CD: Clavien-Dindo 
Table 3: Major 90-day complications according to Clavian-Dindo classification  
 Cause & required treatment  Required intervention 
III Urinary leak 
Uretero-ileal stricture 
 
Wound dehiscence 
Wound abscess  
Retained drain 
Small bowel obstruction (adhesions/ 
incision hernia) 
Hydronephrosis due to stent migration 
 
Pelvic collection 
Melena 
2 
4 
 
2 
2 
1 
2 
 
5 
 
2 
1 
Nephrostomy 
Nephrostomy+/- balloon dilatation 
+/- JJ stent 
Laparotomy 
Incision & drainage of abscess 
GA removal of retained drain 
Laparotomy + adhesiolysis/ hernia 
repair 
Nephrostomy/ radiological 
repositioning of stent 
Radiological drainage 
Gastroscopy-normal 
 
IV Sepsis 8 
 
Intensive care unit admission and 
inotropes 
V Significant bleeding- return to theatre 
Arrhythmia  
Pulmonary embolism 
Carcinomatosis 
1 
1 
1 
1 
N/A 
N/A 
N/A 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: All 90 day complications stratified according to MSKCC classification  
 
Ileal conduit (n=100) Continent diversion  (n=34) 
Haematological 
Transfusion=26 
 
Haematological 
Transfusion=7 
DIC=1  
Cardiovascular 
Arrhythmia=4 
MI=1 
Cardiovascular 
 
Gastrointestinal 
Ileus/ small bowel obstruction=23 
Constipation=8 
Clostridium difficile=4 
Gastrointestinal bleed/coffee ground vomit=4 
Vomiting=6 
Diarrhoea=6 
Enterocutaneous fistula=3 
Malignant ascites=1 
Gastrointestinal 
Ileus/ small bowel obstruction=10 
Constipation=2 
Vomiting=7 
Diarrhoea=8 
 
Genitourinary 
Acute kidney injury=5 
Ureteral obstruction (renal calculi)=1  
Urinary leak=2 
Uretero-ileal stricture=3 
Genitourinary 
Acute kidney injury=2 
Urinary leak=6 
Uretero-ileal stricture=1 
Infection 
Pyrexia of unknown origin=2 
Urosepsis=13 
Chest sepsis=7 
Intra-abdominal collection=9 
Abscess=2 
Line sepsis=2 
Pubis osteomyelitis=1 
Infection 
Pyrexia of unknown origin =3 
Urosepsis=9 
Chest sepsis=1 
Intra-abdominal collection=6 
 
Pulmonary 
 
Pulmonary 
Pulmonary oedema=1 
Surgical 
Incision hernia=3 
Stoma stenosis=1 
Displacement of stent=2 
Lymphedema/ seroma=2 
Surgical emphysema =1 
Surgical 
Retain foreign body=1 
Displacement of stent=3 
 
Thromboembolic  
Pulmonary embolism=1 
Iliac vessel thrombosis=1 
Thromboembolic 
 
Neurological 
Neuropathy=2 
Syncope=3 
Confusion/ hallucination=3 
Neurological 
Neuropathy=3 
Syncope=1 
 
Wound 
Wound infection=3 
Wound dehiscence=2 
Stoma bleeding=1 (silver nitrate) 
Wound 
Wound infection=2 
Wound dehiscence=1 
 
20 
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Table 5: Univariate analysis to evaluate 30-day and 90-day complications  3 
 4 
 5 
BMI: body mass index; ASA: American Society of Anesthesiologist score; AT: 6 
anaerobic threshold; Peak VO2: maximal oxygen consumption; VE/ VCO2: 7 
minute ventilation − carbon dioxide production; NAC: neoadjuvant 8 
chemotherapy; IC: ileal conduit  9 
*men: haemogolbin <13 g/dL, women: haemoglobin <12.5 g/dL,  10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
Variable All 30-day complications 30-day major complications All 90-day complications 90-day major complications 
Preoperative OR (95%) P value OR (95%) P value OR (95%) P value OR (95%) P value 
Gender: male vs female                1.93 (0.86-4.36) 0.110 3.28 (0.72-14.95) 
 
0.107 1.55 (0.66-3.65) 0.315 4.90 (1.1-21.9) 0.024 
Age ≤70 vs ≥ 70 1.35 (0.64-2.82) 0.428 0.86 (0.31-2.39) 0.766 0.83 (0.37-1.85) 0.653 1.05 (0.43-2.56) 0.918 
BMI <25 vs ≥25 1.88 (0.81-4.33) 0.139 1.60 (0.46-5.54) 0.455 0.78 (0.31-1.98) 0.598 1.38 (0.47-4.03) 0.552 
ASA: I & II vs III 2.83 (1.04-7.73) 0.036 3.00 (1.05-8.58) 
 
0.034 1.54 (0.5.3-4.5) 0.425 2.40 (0.90-6.43) 
 
0.076 
AT  1.00 (0.83-1.20) 0.988 1.07 (0.84-1.37) 0.591 0.96 (0.79-1.17) 0.673 1.05 (0.84-1.31) 0.724 
Peak VO2  1.0 (0.92-1.08) 0.923 1.05 (0.95-1.16) 0.325 1.01 (0.92-1.11) 0.827 1.05 (0.96-1.15) 0.254 
VE/ VCO2  0.98 (0.91-1.05) 0.539 0.99 (0.90-1.10) 0.908 0.96 (0.89-1.03) 0.258 0.97 (0.89-1.07) 0.537 
NAC: yes vs no 0.67 (0.33-1.36) 0.264 1.22 (0.46-3.18) 
 
0.692 1.01 (0.46-2.22) 0.923 1.13 (0.47-2.70) 
 
0.788 
Preoperative anaemia: yes vs no* 
 
0.88 (0.44-1.75) 0.712 0.80 (0.31-2.09) 0.654 1.03 (0.48- 2.19) 0.949 1.22 (0.53-2.82) 0.640 
Intraoperative 
Transfusion: yes vs no                       4.22 (1.59-11.20) 0.002 4.50 (1.67-12.08) 
 
0.002 1.68 (0.62-4.52) 0.301 3.16 (1.27-7.88) 
 
0.011 
Type of diversion: IC vs continent                                1.50 (0.67-3.30) 0.323 0.91 (0.31-2.69) 
 
0.858 2.20 (0.83-5.83) 0.109 0.98 (0.37-2.55) 
 
0.959 
Salvage cystectomy: yes vs no 0.53 (0.14-1.98) 0.339 0.58 (0.07-4.82) 
 
0.608 0.36 (0.10-1.33) 0.114 0.40 (0.05-3.29) 
 
0.378 
Cystectomy stage: ≤pT2 vs ≥pT3                                   0.66 (0.33-1.35) 0.255 0.51 (0.17-1.49) 
 
0.211 0.51 (0.23-1.09) 0.079 0.99 (0.42-2.37) 
 
0.989 
21 
 
Table 6: Multivariable analysis of 30-day and 90-day major complications 24 
 25 
 OR (95%) P value 
30-day major complications 
ASA: I & II vs III 1.87 (0.59-5.92) 0.287 
Transfusion: yes vs no                        3.68 (1.28-10.55) 0.016 
90-day major complications  
Gender: male vs female               6.98 (1.45-33.58) 0.015 
Transfusion: yes vs no                      4.33 (1.61-11.67) 0.004 
 26 
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 28 
 29 
 30 
